CRVSCorvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) develops and commercializes soquelitinib, a novel IL-33 inhibitor for atopic dermatitis and asthma. The next catalyst is Oct 16, 2026 — CRVS stock surges 10%, hits 50-DMA for first time. This event will test the market’s appetite for the company’s clinical progress and cash runway.
- CRVS has a narrow product pipeline centered on soquelitinib, with limited near-term revenue.
- The company is heavily dependent on clinical trial outcomes and capital raises to sustain operations.
- Shareholder dilution and cash flow constraints remain persistent risks.
The Read
CRVS’s stock fell about 11% after dilution fears post-$201M offering despite strong soquelitinib data, then dropped nearly 27% on Q4 earnings due to unclear financing but rebounded about 8% after positive Q1 soquelitinib updates.
The schedule
- Fri16Oct
The surge tests whether the stock can sustain momentum from a technical breakout, contrasting with the last rally that stalled on liquidity concerns.
- Tue8Dec
The earnings test focuses on cash runway and guidance reset, differing from the last print where the focus was on revenue mix and margin commentary.
- Tue5Jan
The data tests the drug's efficacy in a new indication, unlike the last trial which focused on a single indication and faced mixed results.
- Tue9Feb
The earnings test focuses on cash burn and guidance, differing from the last print where the focus was on revenue mix and margin commentary.
- Thu6May
The earnings test focuses on cash burn and guidance, differing from the last print where the focus was on revenue mix and margin commentary.
- Thu5Aug
The earnings test focuses on cash burn and guidance, differing from the last print where the focus was on revenue mix and margin commentary.
Past
- Tue9Jun
Actual outcome: Bull · $11.60 at outcome
Corvus reported in-line earnings with an EPS of -$0.15, meeting estimates exactly and demonstrating stable cash burn. Concurrently, the company announced a $5 million investment in Angel Pharmaceuticals to advance clinical trials of soquelitinib in China for atopic dermatitis and asthma. This strategic expansion of their key asset's global development pipeline provided positive momentum, driving an initial 3.8% gain that continued to rally well past the $13.00 bull target in the following weeks.
Q2 2026 results and pipeline update will focus on cash burn, runway after the early-2026 raise, and new efficacy and safety signals from soquelitinib, driving a reassessment of Corvus’ valuation around $11.17.
- Thu7May
Actual outcome: Bull · $15.81 at outcome
Corvus Pharmaceuticals met Q1 2026 EPS estimates at -$0.18 and provided a highly constructive clinical update on its soquelitinib program. The stock rallied 8.4% as investors were encouraged by positive Phase 1 cohort 4 data in atopic dermatitis, the initiation of a Phase 2 trial, and the announcement of upcoming biomarker data supporting the drug's potential to produce drug-free remissions.
Q1 2026 earnings call focused on cash runway after the January equity raise and enrollment progress in the Phase 3 PTCL and Phase 2 atopic dermatitis soquelitinib programs. At a base price of $14.69, a constructive update on trial timelines and burn could lift the stock toward $17.00, while slower enrollment, higher-than-expected cash burn, or hints of future financing needs could push it down toward $17.00.
- Thu12Mar
Actual outcome: Bear · $14.01 at outcome
Corvus Pharmaceuticals reported Q4 2025 EPS of -$0.18, which met analyst estimates, and announced positive safety and efficacy data from cohort 4 of its soquelitinib Phase 1 trial for atopic dermatitis. Despite the positive clinical update, the market reacted negatively to the overall earnings report, driving the stock down 12.5% by the outcome date.
Focus on cash runway, which was critically low in Q3 2025. Positive re-rate requires confirmation of a financing deal to extend runway beyond Q4 2026. Failure to confirm financing will lead to severe asymmetric downside.
- Thu29Jan
Actual outcome: Bear · $18.66 at outcome
CRVS successfully closed its upsized $201 million public offering (priced at $22.15) following a massive rally driven by positive soquelitinib data. However, the expected consolidation near the offering price failed to materialize. Instead, the stock experienced significant short-term selling pressure related to the dilution overhang, causing the price to fall 10.9% and settle near the bear floor ($18.66 vs. $18.50), indicating the market prioritized dilution over the de-risked balance sheet.
Short-term price action following the recent upsized $175M public offering (priced at $22.15). The dilution overhang will be countered by the de-risked balance sheet and cash runway being secured. Consolidation is expected near the offering price.
